Abciximab reduces mortality in diabetics following percutaneous coronary intervention
Deepak L. Bhatt, MDa,
Steven P. Marso, MDa,
A. Michael Lincoff, MD, FACCa,
Katherine E. Wolski, MPHa,
Stephen G. Ellis, MD, FACCa and
Eric J. Topol, MD, FACCa
a Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
View larger version (15K):
[in a new window]
|
Figure 1 The Kaplan-Meier curves for one-year mortality in diabetics versus nondiabetics.
|
|
View larger version (14K):
[in a new window]
|
Figure 2 The Kaplan-Meier curves are shown for one-year mortality in patients randomized to either placebo or abciximab.
|
|
View larger version (22K):
[in a new window]
|
Figure 3 The Kaplan-Meier curves are shown for one-year mortality in diabetics and nondiabetics randomized to either placebo (PL) or abciximab (ABX).
|
|
View larger version (11K):
[in a new window]
|
Figure 4 Hazard ratios are shown for abciximab versus placebo in diabetic patients for each of the three trials analyzed.
|
|
|
